0 169

Cited 15 times in

Effect of the Apolipoprotein Eε4 Allele on the Efficacy and Tolerability of Galantamine in the Treatment of Alzheimer'sDisease

Authors
 Suh G.-H.  ;  Jung H.Y.  ;  Lee C.U.  ;  Oh B.-H.  ;  Lee S.-K.  ;  Lee N.  ;  Kim J.  ;  Kee B.S.  ;  Ko D.  ;  Kim Y.-H.  ;  Ju Y.-S.  ;  Hong I.  ;  Choi S. 
Citation
 DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, Vol.21(1) : 33-39, 2005 
Journal Title
 DEMENTIA AND GERIATRIC COGNITIVE DISORDERS 
ISSN
 1420-8008 
Issue Date
2005
MeSH
Aged ; Alleles* ; Alzheimer Disease/drug therapy* ; Alzheimer Disease/genetics ; Apolipoprotein E4 ; Apolipoproteins E/genetics* ; Delusions/drug therapy ; Delusions/genetics ; Double-Blind Method ; Galantamine/adverse effects ; Galantamine/therapeutic use* ; Hallucinations/drug therapy ; Hallucinations/genetics ; Humans ; Neuropsychological Tests ; Nootropic Agents/adverse effects ; Nootropic Agents/therapeutic use* ; Prospective Studies ; Treatment Outcome
Keywords
16254428
Abstract
OBJECTIVE: To investigate the effect of the apolipoprotein E (ApoE) epsilon4 allele on the efficacy and tolerability of galantamine treatment. METHODS: A total of 202 patients with mild to moderate Alzheimer's disease participated in a 16-week, prospective, multi-center, randomized, double-blind galantamine trial in a Korean population. Patients were assessed at baseline and after 4, 8 and 16 weeks of randomized treatment using the 11-item cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-cog/11), the Clinician's Interview-Based Impression of Change plus Caregiver Input (CIBIC-plus), the Disability Assessment for Dementia Scale (DAD), the Behavioural Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD) and adverse events. ApoE genotypes were determined for all subjects. RESULTS: Of the 202 subjects, 115 carried at least one ApoE epsilon4 allele and 87 did not. In both ApoE epsilon4 carriers and ApoE epsilon4 noncarriers, significant improvements were detected relative to baseline on ADAS-cog/11, CIBIC-plus, DAD and BEHAVE-AD. ApoE epsilon4 noncarriers showed better improvement in mean total BEHAVE-AD score and mean psychosis (delusions and hallucinations) subscale score than ApoE epsilon4 carriers. The incidence of weight loss was significantly higher in ApoE epsilon4 carriers (n = 11; 9.6%) than in ApoE epsilon4 noncarriers (n = 1; 1.2%) during this 16-week study, even though 92% of patients who complained of weight loss completed this 16-week trial successfully. CONCLUSION: ApoE epsilon4 genotype does not affect galantamine-related improvements in cognition, global rating, function and behavior. Longer prospective studies with larger patient populations are required to confirm these new findings.
Full Text
http://www.karger.com/Article/FullText/89217
DOI
10.1159/000089217
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Psychiatry (정신과학교실) > 1. Journal Papers
Yonsei Authors
Oh, Byong Hoon(오병훈)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/151593
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse